Intra-Cellular Therapies Inc (BSP:I2TC34)
R$ 84.24 0 (0%) Market Cap: 8.93 Bil Enterprise Value: 2.80 Bil PE Ratio: 0 PB Ratio: 7.86 GF Score: 31/100

Q4 2023 Intra-Cellular Therapies Inc Earnings Call Transcript

Feb 22, 2024 / 01:30PM GMT
Release Date Price: R$49.53
Operator

Good morning, ladies and gentlemen, and welcome to Intra-Cellular Therapies Fourth Quarter and Year End Financial Results Conference Call. At this time, all participants are in a listen only mode. (Operator Instructions) Again, as a courtesy to other analysts, please limit your questions to one. Please note that today's conference is being recorded.

I would now like to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Please go ahead.

Juan Sabchez
Intra Cellula Therapies Inc - VP, Corporate Communications & IR

Good morning, and thank you all for joining us on our fourth quarter and full year 2023 earnings call. Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Newman, Chief Commercial Officer; Dr. Suresh Burton, Chief Medical Officer, and Laurie Hineline, Chief Financial Officer.

As a reminder, during today's call, we will be making certain forward looking statements. These forward-looking statements are based on current information,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot